Companies › Serum Institute of India
4 active drug programs in 7 registered trials: 4 Phase 2, 2 Phase 1, 1 Phase 3; Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cervavac Quadrivalent human papillomavirus (qHPV) vaccine targeting HPV types 6, 11, 16, 18 | – | Phase 3 | Human Papillomavirus Infection | Dec 2026 |
| Pfs230D1-CRM197 + R21 with Matrix-M1 Recombinant malaria vaccine combining Pfs230D1 antigen (a sexual-stage antigen of Plasmodi | – | Phase 2 | Prevention of Malaria Transmission and Clinical Malaria | Nov 2027 |
| R21 Recombinant fusion protein of Plasmodium falciparum circumsporozoite protein (CSP) fused t | – | Phase 2 | Prevention of Malaria Transmission and Clinical Malaria; Malaria,Falciparum | Nov 2027 |
| Recombinant Poliomyelitis Vaccine (rPV) Recombinant poliomyelitis virus-like particles (VLP) | – | Phase 1 | Polio Immunity | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07688369 | Recombinant Poliomyelitis Vaccine (rPV) | Phase 1 | Polio Immunity | Infectious disease | Nov 2026 |
| NCT06281119 | Cervavac | Phase 3 | Human Papillomavirus Infection | Infectious disease | Dec 2026 |
| NCT07183371 | R21 | Phase 2 | Malaria,Falciparum | Infectious disease | Mar 2027 |
| NCT06958198 | R21 | Phase 1 | Malaria,Falciparum | Infectious disease | Mar 2027 |
| NCT07147400 | Pfs230D1-CRM197 + R21 with Matrix-M1 | Phase 2 | Prevention of Malaria Transmission and Clinical Malaria | Infectious disease | Nov 2027 |
| NCT07147400 | Pfs230D1-CRM197 + R21 with Matrix-M1 | Phase 2 | Prevention of Malaria Transmission and Clinical Malaria | Infectious disease | Nov 2027 |
| NCT07147400 | R21 | Phase 2 | Prevention of Malaria Transmission and Clinical Malaria | Infectious disease | Nov 2027 |
No annotated target.
–
CanSino Biologics Eveliqure Biotechnologies Sanaria Brii Biosciences SIGA Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.